Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator SP-624
MORRISVILLE, N.C.--(BUSINESS WIRE) April 16, 2024 -- Arrivo BioVentures announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
This...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials